Continued treatment with the anti-interleukin (IL)-23 monoclonal antibody guselkumab generated high efficacy response rates in patients with moderate-to-severe plaque psoriasis, according to findings from the ongoing phase III VOYAGE 2* trial presented at the 2018 American Academy of Dermatology Annual Meeting (AAD 2018) held in San Diego, California, US.
The approved psoriasis therapy ustekinumab also reduces aortic vascular inflammation, along with improved psoriasis severity, compared with placebo in patients with moderate-to-severe psoriasis, according to the VIP-U* study presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, US.
The humanized IgG1 monoclonal antibody risankizumab cleared plaque psoriasis better than ustekinumab and placebo in two phase III head-to-head studies. Risankizumab also appeared to be superior to ustekinumab or placebo in many endpoints.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.